Skip to content

Application of Linked Color Imaging(LCI) in Diagnosis of Early Gastric Cancer(EGC)

Application of Linked Color Imaging(LCI) in Diagnosis of Early Gastric Cancer(EGC): a Multicenter,Prospective, Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03661671
Enrollment
2400
Registered
2018-09-07
Start date
2018-01-01
Completion date
2019-01-01
Last updated
2018-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastric Cancer

Keywords

Linked-color imaging, Detection

Brief summary

the purpose of this study is to evaluate application value of LCI in the diagnosis of early gastric cancer.

Detailed description

The detection rate of early gastric cancer is still very low in China. The investigators need a new and effective screening method to improve the detection rate. LCI (linked-color imaging)is a new model of laser endoscopy which can provide brighter image. LCI can provide clear image which can make red part redder and white part whiter, so suspicious lesion could be found easier. The study of this randomized controlled trial is to discuss effectiveness of LCI in the diagnosis of early gastric cancer and to find a new method to improve the detection rate of early gastric cancer in China.

Interventions

DIAGNOSTIC_TESTLCI+white light

Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia

Sponsors

Shanxi Province Cancer Hospital
CollaboratorOTHER
First People's Hospital of Hangzhou
CollaboratorOTHER
307 Hospital of PLA
CollaboratorOTHER
Jiangsu Province Hospital of Traditional Chinese Medicine
CollaboratorOTHER
The First Affiliated Hospital of Anhui Medical University
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
Zhongshan Hospital Xiamen University
CollaboratorOTHER
Chongqing University Cancer Hospital
CollaboratorOTHER
Guilin Medical University, China
CollaboratorOTHER
Guangdong Provincial Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
Wuhan University
CollaboratorOTHER
Xi'an Central Hospital
CollaboratorOTHER
Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Parallel assignment

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. High-risk group of gastric cancer: H. pylori infection; previously suffering from chronic atrophic gastritis, intestinal metaplasia, gastric ulcer, gastric polyps, residual stomach after surgery, hypertrophic gastritis, malignant anemia and other precancerous diseases of gastric cancer; 2. First degree relatives of patients with gastric cancer; 3. There are other high risk factors for gastric cancer (high salt, salted diet, smoking, heavy drinking, etc.). 4. Patients with early gastric cancer treated with endoscopic therapy (ESD, EMR). 5. The informed consent has been signed.

Exclusion criteria

1. The TNM classification of cancer is consistent with those diagnosed by T2 above. 2. Patients with abnormal blood coagulation function or taking anticoagulants can not biopsy. 3. There were contraindications for gastroscopy. 4. A patient without self judgement; 5. Those who did not sign informed consent. 6. Previous gastroscopy has found suspicious lesions requiring careful examination.

Design outcomes

Primary

MeasureTime frameDescription
Detection rate of gastric neoplastic lesionimmediately following the procedureInclude early gastric caner,high grade dysplasia low grade dysplasia and adenoma

Secondary

MeasureTime frameDescription
Specificity of detecting gastric neoplastic lesionimmediately following the procedureInclude early gastric caner,high grade dysplasia low grade dysplasia and adenoma
Sensitivity of detecting gastric neoplastic lesionimmediately following the procedureInclude early gastric caner,high grade dysplasia low grade dysplasia and adenoma

Countries

China

Contacts

Primary ContactDong Wang, M.D
dongwang0901@sina.com8613816758802
Backup ContactJie Gao, M.D
jesseegao@163.com8613761272863

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026